|
Post by rockstarrick on Nov 9, 2016 21:27:16 GMT -5
Mango might have to stop public information sharing if this continues! I appreciate it 👍
|
|
|
Post by mango on Nov 10, 2016 9:58:36 GMT -5
The Teuza fund Israel domain—access remains protected by username and password
The Teuza fund .com domain remains a 404
How does the old saying go? Follow to the target not the arrow? Follow the money or something like that😶
|
|
|
Post by mango on Nov 10, 2016 13:42:32 GMT -5
I watched a short docu video on Martin Shkreli a while back, and in it Martin Shkreli requests the interviewer to play a game of chess while they chat and drink a bottle of "fine wine". As the interview progresses and Shkreli makes flaunting remarks and comments while basking in his narcissistic bubble of sunshine, and capturing the moment in a sea of blissful arrogance, Mr. Shkreli showcases his chess playing ability as he describes "the real world" and "who he really is". One can learn a lot about Mr. Shkreli just by knowing he plays chess and not backgammon. Chess is a game of perfect information. Backgammon is a game of perfect information, but with chance. In backgammon a player must continuously adapt to the evolving landscape and use different strategies and tactics along the way. A very skilled backgammon player will always win over the lesser as they progress through the match, causing the luck factor to decline significantly as each game is played until the match is won. Mango knows very little about the stock market, but mango does play backgammon and knows that MannKind is not a typical company in the biotech sector, and perhaps of any sector. Unfortunately for Mr. Martin Shkreli, MannKind in the stock world is like that of a game of backgammon, not chess. I wonder what Mr. Alfred Mann and his close personal friend and business acquaintance, Avi Kerbs, the CEO of Teuza, did for fun and enjoyment over there in Israel? I hear backgammon is quite popular... Sorry Mr. Martin Shkreli, you lose. m.youtube.com/watch?v=2PCb9mnrU1g
|
|
|
Post by zuegirdor on Nov 10, 2016 14:26:00 GMT -5
I watched a short docu video on Martin Shkreli a while back, and in it Martin Shkreli requests the interviewer to play a game of chess while they chat and drink a bottle of "fine wine". As the interview progresses and Shkreli makes flaunting remarks and comments while basking in his narcissistic bubble of sunshine, and capturing the moment in a sea of blissful arrogance, Mr. Shkreli showcases his chess playing ability as he describes "the real world" and "who he really is". One can learn a lot about Mr. Shkreli just by knowing he plays chess and not backgammon. Chess is a game of perfect information. Backgammon is a game of perfect information, but with chance. In backgammon a player must continuously adapt to the evolving landscape and use different strategies and tactics along the way. A very skilled backgammon player will always win over the lesser as they progress through the match, causing the luck factor to decline significantly as each game is played until the match is won. Mango knows very little about the stock market, but mango does play backgammon and knows that MannKind is not a typical company in the biotech sector, and perhaps of any sector. Unfortunately for Mr. Martin Shkreli, MannKind in the stock world is like that of a game of backgammon, not chess. I wonder what Mr. Alfred Mann and his close personal friend and business acquaintance, Avi Kerbs, the CEO of Teuza, did for fun and enjoyment over there in Israel? I hear backgammon is quite popular... Sorry Mr. Martin Shkreli, you lose. m.youtube.com/watch?v=2PCb9mnrU1gWow. thanks for posting the Shkreli vid. As an "older" person who has known and observed many poeple over the years, I have watched as my skill in understanding personality and personal psychology grow. I have tended to villify this charlatan, but forgotten that like all monsters, he was once an innocent child (not to say he is not dangerous. I clicked te start arrow on this excpecting to have my darker passions provoked. But I was struck immediately at what an almost normal guy he was, a typical nerd. But more than that, the size, character and location of his wound was obvious and became clearer as the interview went along. I am not saying I have an unconditional sympathy for or acceptance of the compromises of character he has made in order to advance his fortune. He has a lot to learn, as does the system that has allowed him the reign he has seized for himself. But, he could change and thereby change "how the world works" as he says. He seems human after all. Exploitation of the weaknesses and vulnerabilities of a system upon which all of us depend for our lives is for him a cure or treatment (or revenge?) for the pain of casual and routine "child abuse" inherent in growing up. It is like the drugs he pedals and bets on as a trader. He needs the thrill of control of a drug market in order to distract him from his pain. But whatever he thinks of himself, he is not involved in drug development. Until he puts some serious study into disease and patient care and the development of new therapies he is just a market trader. Markets are Reactive. The kind of market tricks and trade he exploits are new and transitory. Its proponents are egocentric, lacking humility and appreciation for how much they depend upon society and the embodied labors of all who came before them. The science of Drug development is Proactive. All scientists must research the standing knowledge that precedes their work. They know they stand on the shoulder of giants and gnats (drosophila?) both. I hope when he finally grows up he will take a more mature view of the respective roles of markets and medicine. As has been said of him in the congressional hearings, he could "do much good if he chose to". Always valuable to glimpse the humanity in those we perceive as foes....especially when things don't feel like they are going your way.
|
|
|
Post by mango on Nov 10, 2016 18:02:29 GMT -5
I watched a short docu video on Martin Shkreli a while back, and in it Martin Shkreli requests the interviewer to play a game of chess while they chat and drink a bottle of "fine wine". As the interview progresses and Shkreli makes flaunting remarks and comments while basking in his narcissistic bubble of sunshine, and capturing the moment in a sea of blissful arrogance, Mr. Shkreli showcases his chess playing ability as he describes "the real world" and "who he really is". One can learn a lot about Mr. Shkreli just by knowing he plays chess and not backgammon. Chess is a game of perfect information. Backgammon is a game of perfect information, but with chance. In backgammon a player must continuously adapt to the evolving landscape and use different strategies and tactics along the way. A very skilled backgammon player will always win over the lesser as they progress through the match, causing the luck factor to decline significantly as each game is played until the match is won. Mango knows very little about the stock market, but mango does play backgammon and knows that MannKind is not a typical company in the biotech sector, and perhaps of any sector. Unfortunately for Mr. Martin Shkreli, MannKind in the stock world is like that of a game of backgammon, not chess. I wonder what Mr. Alfred Mann and his close personal friend and business acquaintance, Avi Kerbs, the CEO of Teuza, did for fun and enjoyment over there in Israel? I hear backgammon is quite popular... Sorry Mr. Martin Shkreli, you lose. m.youtube.com/watch?v=2PCb9mnrU1gWow. thanks for posting the Shkreli vid. As an "older" person who has known and observed many poeple over the years, I have watched as my skill in understanding personality and personal psychology grow. I have tended to villify this charlatan, but forgotten that like all monsters, he was once an innocent child (not to say he is not dangerous. I clicked te start arrow on this excpecting to have my darker passions provoked. But I was struck immediately at what an almost normal guy he was, a typical nerd. But more than that, the size, character and location of his wound was obvious and became clearer as the interview went along. I am not saying I have an unconditional sympathy for or acceptance of the compromises of character he has made in order to advance his fortune. He has a lot to learn, as does the system that has allowed him the reign he has seized for himself. But, he could change and thereby change "how the world works" as he says. He seems human after all. Exploitation of the weaknesses and vulnerabilities of a system upon which all of us depend for our lives is for him a cure or treatment (or revenge?) for the pain of casual and routine "child abuse" inherent in growing up. It is like the drugs he pedals and bets on as a trader. He needs the thrill of control of a drug market in order to distract him from his pain. But whatever he thinks of himself, he is not involved in drug development. Until he puts some serious study into disease and patient care and the development of new therapies he is just a market trader. Markets are Reactive. The kind of market tricks and trade he exploits are new and transitory. Its proponents are egocentric, lacking humility and appreciation for how much they depend upon society and the embodied labors of all who came before them. The science of Drug development is Proactive. All scientists must research the standing knowledge that precedes their work. They know they stand on the shoulder of giants and gnats (drosophila?) both. I hope when he finally grows up he will take a more mature view of the respective roles of markets and medicine. As has been said of him in the congressional hearings, he could "do much good if he chose to". Always valuable to glimpse the humanity in those we perceive as foes....especially when things don't feel like they are going your way. I have no sympathy for him, regardless of what, if anything, caused him to be who he is. He is a grown man. He still bashes MannKind. He stole millions of dollars from his shareholders, lied to them, for his own gain. He is a narcissist, and that is the only thing I see. If you watched the Congressional Meeting with Shkreli, you would see the complete and utter lack of respect he has for anyone. The only thing that can change a narcissist is being humbled, IMO, and I am not sure if I can adopt the ideology of looking past what people are doing while they are currently doing it. You do realize the damage he has done to not only MannKind, but to other companies and shareholders as well. And he is putting himself before patients by doing so. The exact opposite of how I think. I respect your opinion, but he was even extremely rude and arrogant to the young woman that interviewed him.
|
|
|
Post by mango on Nov 10, 2016 22:27:57 GMT -5
DONALD TRUMP AND THE ISRAELI CONNECTIONS—CONTINUED • Donald Trump's top Israel Advisors will be two Jewish attorneys, Jason Dov Greenblatt and David M. Friedman•Jason Dov Greenblatt —Trump's real estate attorney for over 19 years —Trump's Number 1 Israel Advisor •David M. Friedman —Bankruptcy and real estate attorney at Kasowitz, Benson Torres, Friedman law firm —“I do rely on him as a consultant on Israel,” Trump said of Greenblatt at an April 14 meeting with Jewish reporters, including JTA. “He’s a person who truly loves Israel. I love to get advice from people that know Israel, but from people that truly love Israel.” — Greenblatt recalled the time he was leading a complex negotiation when he sheepishly told Trump he had to stop everything for a three-day Jewish holiday. —"He said, ‘Go home, go pray, be with your family and we’ll pick it up after the holiday,’” Greenblatt said of Trump. “He didn’t just not make an issue of it; he made me feel great about it.”
forward.com/news/national/338915/no-experience-necessary-meet-trumps-orthodox-israel-advisor/
— Under a Trump presidency, the United States will “finally accept the longstanding congressional mandate to recognize Jerusalem as the undivided capital of the State of Israel,” according to his campaign’s description of the meeting, which was closed to the press.
—Officials in the Prime Minister’s Office said he was accompanied to the meeting by Israeli Ambassador to the United States Ron Dermer, and that Trump was joined by his son-in-law, Jared Kushner.
—Israeli officials said that Netanyahu thanked Trump for his friendship and support of the Jewish state.
m.jpost.com/Israel-News/Politics-And-Diplomacy/Netanyahu-meets-with-Trump-in-New-York-468662#article=161847NjQ3RUJDRTRERDJCMjkzQjc5ODQ5QTE1QjE4ODk2RDg=
—In a meeting with Orthodox Jews Thursday, Donald Trump named his two advisors on Israel - and the names bespeak good news for nationalists who believe in Israel's right to the Biblical heartland of Judea and Samaria.
—The two are Trump's chief lawyer, Jason D. Greenblatt, a real estate attorney from Teaneck, New Jersey, and another real estate lawyer, bankruptcy expert David M. Friedman of the Kasowitz law firm.
—"I don’t think I can find better,” Trump said. “Jason’s very much a consultant to me on Israel, on everything. He’s a tremendously talented lawyer, one of the great real estate lawyers of the City of New York, and he has tremendous passion for Israel. When he goes on vacation, he goes to Israel.”
www.israelnationalnews.com/News/News.aspx/210953
—It is Mr. Trump’s firm hope — and the hope of peace-loving people everywhere — that the Palestinian leaders will soon eschew violence and hatred, just as the Egyptian people did four decades ago. Though the current conditions may not be ripe for an immediate renewal of the peace process, Mr. Trump will engage the Israeli and Palestinian leaders in constructive dialogue and work to lay the foundation for a historic peace."
—If fortunate enough to be elected president, Donald Trump will renew the historic bond between our two countries and bring to the Oval Office a recognition that Israel is America’s great friend, a force for justice and peace and the one true democracy in the Middle East.
blogs.timesofisrael.com/a-trump-presidency-means-a-safer-israel/
|
|
|
Post by mango on Nov 10, 2016 22:28:29 GMT -5
Everything below is pure soeculation of my own. Except the part about Donald Trump and vaccines and manufacturing, creating jobs, and providing fewer, cheaper, and healthier alternatives to present vaccines DONALD TRUMP AND TECHNOVAX/MANNKIND CONNECTIONS •It is well understood what Donald Trump's stance is on vaccines. The controversy surrounding vaccines causing Autism is a huge issue for Donald Trump. He fully supports vaccines, BUT he wants people to have to take fewer of them, and be given at longer intervals. •This is exactly where TechnoVax will come in. Inhaled RSV and Flu vaccines by TechnoVax and MannKind will be fast tracked for the safety of public health because they contain no viral genetic material and are non-invasive and safer, thus providing citizens, *especially children*, a medical alternative to needles. •TechnoVax and MannKind Inhaled Vaccines — Below highlights KEY advantages that TechnoVax and MannKind have that match exactly what Donald Trump wants for the future of vaccines to be. It is almost as if TechnoVax wrote this specifically for Donald Trump! * Extended Shelf Life and Elimination of Cold Chain results in improved distribution costs and inventory management
* Best Route of Immunization (mucosal surface – respiratory tract) * Increased Patient Acceptance (inhaled vs. injection)
* Cross Protection against multiple influenza strains.* Reduced frequency of immunization (longer protection).* Improved production Planning (manufacturing, storage and distribution).* Rapid and Flexible Cell Culture Manufacturing Systems. * Platform technology suitable for developing and producing multiple distinct vaccines.
* Eliminates the need for eggs or live/attenuated viruses during production.
* Highly immunogenic vaccines eliciting robust immune responses.* Safe product without the need for inactivation as it uses non-infectious, non-pathogenic organisms for humans.* Reduced safety concerns during production requiring no containment facilities.
* High yield, larger production capabilities, shorter production time and lower cost.
* Reduced Manufacturing Costs & Capital requirements* Creation of Master Cell Banks (Continuous Cell Line System). * Rapid Response to emerging pandemic or epidemic influenza virus strains due to fast and flexible systemtechnovax.com/technology-advantages/technovax.com/inhaled-powder-vaccines/technovax.com/rsv-vaccine/technovax.com/universal-flu-vaccine/
|
|
|
Post by mango on Nov 12, 2016 13:42:44 GMT -5
REVIEWING TRUMP'S POSITION ON CANNABIS—PURE SPECULATION • Both domains for Teuza are still—username/password protected and 404. • Where does Trump stand on cannabis? — Trump will follow what Israel does. Which equals Medical Cannabis being made legal on the federal level, and, since we are divided into states, leaving it up to the states to decide on recreational use. Trump has said in the past he would NOT consider recreational use a crime, but that it would be up to the states to decide on the issue. —He could change his mind on that particular aspect, but we do know for certain he is for medical use. • Let's Review: "I think medical marijuana 100%." —Donald Trump, February 25, 2015 Fast forward to 22:05 www.c-span.org/video/?324558-11/donald-trump-remarks-"I think medical should happen—right? Don't we agree? I mean, I think so. And then I really believe you should leave it up to the states. It should be a state situation." —Donald Trump, October 29, 2015 answering a question on legalization of marijuana at the federal level. m.youtube.com/watch?v=jWAADm69dV8• Reflections — Trump will use Israel's expertise.How? Israel has had medical cannabis for patients and are the pioneers and experts. A team consisting of the world's experts and authority on cannabis will advise Trump and United States medical doctors on cannabis/cannabis derived medicine, and, more specifically, the endocannabinoid system. This team is Phytecs. — I have been keeping up with Israel's news on this and I think that Trump will use their guidance as a model for establishing medical cannabis therapies for patients in the USA. —Patents. This is the fork in the road. Big Pharma won't be able to monopolize. Medical will go towards creating compounds that target specific receptor sites in and on the body. Big Pharma loves patents. Patents are not entirely necessary when it comes to the ECS. I believe this is where it will lead to and end up becoming a major part of human health. On to compounds.. What compounds? CBD compounds. Caryodiol. Beta-Caryophyllene. There will be great compounds that target the endocannabinoid system with a specific purpose and function. Getting high is not medicine. — Medical>Diseases, illnesses, disorders, cancers, homeostasis, etc Alfred Mann>AMIT>Israel>Raphael Mechoulam>Donald Trump>Israel — How medical cannabis is done in Israel and the outcomes of it will be the blueprints for how Trump handles it here. He wants to be the best. To be the best you have to have the best. Who is the best? Phytecs.
|
|
|
Post by rockstarrick on Nov 12, 2016 14:17:45 GMT -5
Very interesting mango, thanks for sharing.
|
|
|
Post by mango on Nov 27, 2016 21:41:15 GMT -5
|
|
|
Post by mango on Nov 27, 2016 21:53:50 GMT -5
• Teuza Fund Investment Philosophy — Teuza invests in Israeli or Israeli-based ventures, based on diversification, rather than concentrating on specific fields. — Teuza invests in all stages of venture funding, from seed to start-up, through later stage growth. — We seek breakthrough technologies and entrepreneurs with a vision that could make a real difference in their sector— We focus on selected high-growth technologies that have an "unfair advantage"— We seek companies that fill a true and measurable customer need, having a potential market size of at least $200 million worldwide.— We seek representation on the company's board of directors as a way of actively supporting management with operational and strategic issues— Our preferred investment size typically ranges from $1,000,000 to $2,000,000.www.teuzafund.com/philosophy.html
|
|
|
Post by mango on Nov 27, 2016 22:13:18 GMT -5
• Teuza Fund Management Philosophy: Our Added Value — Active and ongoing "hands on" assistance to portfolio companies by: 1. Board Level participation 2. Strategic planning and decision support 3. Ongoing assistance to and working with management to develop creative solutions 4. Global marketing strategy formulation 5. Connections and entry to new markets 6. Recruitment of key positions Funding: — Teuza plays an active role in it's portfolio companies funding needs including: 1. Supporting subsequent financing round 2. Finding strategic investors 3. Guiding the process to an exit by M&A or IPO at the right timing — To date, Teuza helped in raising over $300 million for it's portfolio companies Global network — Teuza provides significant added value to the portfolio companies as it enables them access to its global network our portfolio companies — Strategic alliances Teuza believes that the best way to succeed is by forming strategic alliances with the world's leading companies, therefore, we assist portfolio companies in identifying synergistic partnerships and alliances www.teuzafund.com/management_philosophy.html• Bioness is a portfolio company, which Teuza holds 3% • Sealantis—An Alfred Mann Institute at the Technion spin out company, which Teuza holds 13%. This company is doing big things and was mentioned by David Hankin CEO of the AMF in an article I posted not long ago. www.teuzafund.com/portfolio.html
|
|
|
Post by mango on Nov 27, 2016 22:20:50 GMT -5
• Sealantis — Sealantis develops innovative products based on a proprietary platform of alga-mimetic tissue adhesives, for a variety of applications and clinical needs in surgical adhesion, leakage control, adhesion-prevention and drug delivery. www.sealantis.co.il• The company was founded at AMIT - Alfred Mann Institute at the Technion by Prof. Havazelet Bianco-Peled, a renown biopolymer researcher. www.teuzafund.com/Sealantis.html
|
|
|
Post by mango on Nov 27, 2016 23:03:28 GMT -5
Teuza appears inactive since 2012? Think again... • Track Record & Successes — To date, Teuza has invested in 27 companies a total amount of $54 million and had 15 exits. — In the years 2010-2014 Teuza exercised its shares in Nova for the total sum of $12.2 million. — In 2012 Teuza realized 3% of its stock in Bioness for a valuation of $230 million.— In 2011 Teuza realized its holdings in Persay for $ 1.1 million. — In 2010 Teuza realized 3% of its stocks in Bioness for valuation of $200M.— In 2010 Teuza realized some of its holdings in Nova for valuation of over $200M, 100 times the original investment.— In 2007, N.E.S.S was acquired by Bioness for $75 million, out of which $28 million in cash and the rest in stocks of Bioness.— In 2000, Nova measuring instruments Ltd. went public on NASDAQ stock exchange at a post money valuation of $285 million. Teuza's original investment in Nova was $900,000. — In 1999, Waveaccess was acquired by Lucent for $60 million. Teuza's profit from this realization was 43 million NIS. www.teuzafund.com/track.html
|
|
|
Post by mango on Nov 27, 2016 23:24:14 GMT -5
• Teuza's Largest Shareholder is Alfred Mann — The company’s largest current shareholder is American entrepreneur Alfred Mann, with a 22% holding. To date, Mann has sold seven companies for a total of $9US billion. Teuza Management and Development 1991 Ltd. owns 8% of the company, and the rest is held by foreign investors and the public. — This is from 2010 (only version via archive.org) www.teuzafund.com/docs/126.pdfweb.archive.org/web/*/http://www.teuzafund.com/docs/126.pdf• The sale reduces Teuza's stake in the medical device company from 4.5% to 3%, and increases Mann's stake to 24.5%.— Teuza - A Fairchild Technology Venture Ltd. (TASE:TUZA) has exercised an option to sell 1.2 million shares in portfolio company Bioness Ltd. to Alfred Mann for $3.3 million. The sale reduces Teuza's stake in Bioness from 4.5% to 3%, and increases Mann's stake to 24.5%. — From 2012 www.globes.co.il/en/article-1000723359
|
|